Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
OXUR | Brussels | EUR | Real-time | |
OXURb | BATS Europe | EUR | Delayed | |
0G99 | London | EUR | Real-time |
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist, which is in Phase II clinical trials for the treatment of DME. Oxurion NV has collaboration agreements with Bicycle Therapeutics and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Name | Age | Since | Title |
---|---|---|---|
Anat Loewenstein | - | 2023 | Non-Executive, Independent Director |
Nathalie Laarakker | - | 2023 | Non-Executive, Independent Director |
Charles Paris de Bollardiere | 68 | 2023 | Independent Chairman of the Board |
Pascal Ghoson | - | 2023 | CEO, CFO & Executive Director |
James Hartmann | 57 | 2023 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review